MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemia

• Published in: Clinical epigenetics Vol. 16; no. 1; pp. 17 - 12
• Main Authors: Šestáková, Šárka, Šálek, Cyril, Kundrát, Dávid, Cerovská, Ela, Vydra, Jan, Ježíšková, Ivana, Folta, Adam, Mayer, Jiří, Cetkovský, Petr, Remešová, Hana
• Format: Journal Article
• Language: English
• Published: Germany BioMed Central Ltd 22-01-2024; BioMed Central; BMC
• Subjects: Acute myeloid leukemia; Adult; Cancer; DNA; DNA Methylation; Epigenetic inheritance; Epigenetics; Epigenomics; Genes; Genetic aspects; Humans; Leukemia; Leukemia, Myeloid, Acute - diagnosis; Leukemia, Myeloid, Acute - genetics; Medical prognosis; Methylation; Mutation; NGS; Pathogenesis; Prognosis; Progression-Free Survival; Regression analysis; Standard scores; Survival; DNA methylation; Prognosis; NGS; Acute myeloid leukemia
• ISSN: 1868-7083; 1868-7075; 1868-7083; 1868-7075
• DOI: 10.1186/s13148-024-01625-x

Changes in DNA methylation are common events in the pathogenesis of acute myeloid leukemia (AML) and have been repeatedly reported as associated with prognosis. However, studies integrating these numerous and potentially prognostically relevant DNA methylation changes are lacking. Therefore, we aimed for an overall evaluation of these epigenetic aberrations to provide a comprehensive NGS-based approach of DNA methylation assessment for AML prognostication.
We designed a sequencing panel targeting 239 regions (approx. 573 kb of total size) described in the literature as having a prognostic impact or being associated with AML pathogenesis. Diagnostic whole-blood DNA samples of adult AML patients divided into a training (n = 128) and a testing cohort (n = 50) were examined. The libraries were prepared using SeqCap Epi Enrichments System (Roche) and sequenced on MiSeq instrument (Illumina). Altogether, 1935 CpGs affecting the survival (p < 0.05) were revealed in the training cohort. A summarizing value MethScore was then calculated from these significant CpGs. Patients with lower MethScore had markedly longer overall survival (OS) and event-free survival (EFS) than those with higher MethScore (p < 0.001). The predictive ability of MethScore was verified on the independent testing cohort for OS (p = 0.01). Moreover, the proof-of-principle validation was performed using the TCGA dataset.
We showed that comprehensive NGS-based approach of DNA methylation assessment revealed a robust epigenetic signature relevant to AML outcome. We called this signature MethScore and showed it might serve as a strong prognostic marker able to refine survival probability of AML patients.